Induction of imatinib metabolism by hypericum perforatum [3]

Blood

Volumn 104, Issue 4, 2004, Pages 1229-1230

  Smith, Patrick F ^a   Bullock, Julie M ^b   Booker, Brent M ^b   Haas, Curtis E ^b   Berenson, Charles S ^b   Jusko, William J ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CGP 74588; DRUG METABOLITE; HYPERICUM PERFORATUM EXTRACT; IMATINIB; PHENYTOIN; RIFAMPICIN;

CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; LETTER; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL;

EID: 3843073066     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1240     Document Type: Letter

References (7)

1. Durr D, Stieger B, Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598-604.
2. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
4. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637-1647.
5. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8:3034-3038.
6. Product Information: Gleevec, imatinib. East Hanover, NJ: Novartis Pharmaceuticals; 2004.
7. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935-942.